Cell-permeable peptide targeting the Nrf2-keap1 interaction: A potential novel therapy for global cerebral ischemia

Jingyi Tu, Xi Zhang, Ying Zhu, Yongxin Dai, Ning Li, Fang Yang, Quanguang Zhang, Darrell W Brann, Ruimin Wang

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The current study examined efficacy of a small Tat (trans-activator of transcription)-conjugated peptide activator of the Nrf2 (nuclear factor-E2-related factor-2) antioxidant/cell-defense pathway as a potential injury-specific, novel neuroprotectant against global cerebral ischemia (GCI).A competitive peptide, DEETGE-CAL-Tat, was designed to facilitate Nrf2 activation by disrupting interaction of Nrf2 with Keap1 (kelch-like ECH-associated protein 1), a protein that sequesters Nrf2 in the cytoplasm and thereby inactivates it. The DEETGECAL-Tat peptide contained the critical sequence DEETGE for the Nrf2-Keap1 interaction, the cell transduction domain of the HIV-Tat protein, and the cleavage sequence of calpain, which is sensitive to Ca2+ increase and allows injury-specific activation of Nrf2. Using an animal model of GCI, we demonstrated that pretreatment with the DEETGE-CAL-Tat peptide markedly decreased Nrf2 interaction with Keap1 in the rat hippocampal CA1 region after GCI, and enhanced Nrf2 nuclear translocation and DNA binding. The DEETGE-CAL-Tat peptide also induced Nrf2 antioxidant/cytoprotective target genes, reduced oxidative stress, and induced strong neuroprotection and marked preservation of hippocampal-dependent cognitive function after GCI. These effects were specific as control peptides lacked neuroprotective ability. Intriguingly, the DEETGE-CAL-Tat peptide effects were also injury specific, as it had no effect upon neuronal survival or cognitive performance in sham non ischemic animals. Of significant interest, peripheral, post ischemia administration of the DEETGE-CAL-Tat peptide from days 1-9 after GCI also induced robust neuroprotection and strongly preserved hippo campal-dependent cognitive function. Based on its robust neuro protective and cognitive-preserving effects, and its unique injury-specific activation properties, the DEETGE-CAL-Tat peptide represents a novel, and potentially promising new therapeutic modality for the treatment of GCI.

Original languageEnglish (US)
Pages (from-to)14727-14739
Number of pages13
JournalJournal of Neuroscience
Volume35
Issue number44
DOIs
StatePublished - Nov 4 2015

Fingerprint

NF-E2-Related Factor 2
Trans-Activators
Brain Ischemia
Peptides
Therapeutics
Wounds and Injuries
Cognition
Human Immunodeficiency Virus rev Gene Products
Antioxidants
Hippocampal CA1 Region
Aptitude
Calpain
Neuroprotective Agents
Cell Communication
Cytoplasm
Oxidative Stress
Ischemia
Animal Models

Keywords

  • Cardiac arrest
  • Cognitive defect
  • Hippocampus CA1 region
  • Neuroprotection
  • Peptide
  • Reactive oxidative species

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Cell-permeable peptide targeting the Nrf2-keap1 interaction : A potential novel therapy for global cerebral ischemia. / Tu, Jingyi; Zhang, Xi; Zhu, Ying; Dai, Yongxin; Li, Ning; Yang, Fang; Zhang, Quanguang; Brann, Darrell W; Wang, Ruimin.

In: Journal of Neuroscience, Vol. 35, No. 44, 04.11.2015, p. 14727-14739.

Research output: Contribution to journalArticle

Tu, Jingyi ; Zhang, Xi ; Zhu, Ying ; Dai, Yongxin ; Li, Ning ; Yang, Fang ; Zhang, Quanguang ; Brann, Darrell W ; Wang, Ruimin. / Cell-permeable peptide targeting the Nrf2-keap1 interaction : A potential novel therapy for global cerebral ischemia. In: Journal of Neuroscience. 2015 ; Vol. 35, No. 44. pp. 14727-14739.
@article{68e75b8867f6437b885fe371b5df7b6a,
title = "Cell-permeable peptide targeting the Nrf2-keap1 interaction: A potential novel therapy for global cerebral ischemia",
abstract = "The current study examined efficacy of a small Tat (trans-activator of transcription)-conjugated peptide activator of the Nrf2 (nuclear factor-E2-related factor-2) antioxidant/cell-defense pathway as a potential injury-specific, novel neuroprotectant against global cerebral ischemia (GCI).A competitive peptide, DEETGE-CAL-Tat, was designed to facilitate Nrf2 activation by disrupting interaction of Nrf2 with Keap1 (kelch-like ECH-associated protein 1), a protein that sequesters Nrf2 in the cytoplasm and thereby inactivates it. The DEETGECAL-Tat peptide contained the critical sequence DEETGE for the Nrf2-Keap1 interaction, the cell transduction domain of the HIV-Tat protein, and the cleavage sequence of calpain, which is sensitive to Ca2+ increase and allows injury-specific activation of Nrf2. Using an animal model of GCI, we demonstrated that pretreatment with the DEETGE-CAL-Tat peptide markedly decreased Nrf2 interaction with Keap1 in the rat hippocampal CA1 region after GCI, and enhanced Nrf2 nuclear translocation and DNA binding. The DEETGE-CAL-Tat peptide also induced Nrf2 antioxidant/cytoprotective target genes, reduced oxidative stress, and induced strong neuroprotection and marked preservation of hippocampal-dependent cognitive function after GCI. These effects were specific as control peptides lacked neuroprotective ability. Intriguingly, the DEETGE-CAL-Tat peptide effects were also injury specific, as it had no effect upon neuronal survival or cognitive performance in sham non ischemic animals. Of significant interest, peripheral, post ischemia administration of the DEETGE-CAL-Tat peptide from days 1-9 after GCI also induced robust neuroprotection and strongly preserved hippo campal-dependent cognitive function. Based on its robust neuro protective and cognitive-preserving effects, and its unique injury-specific activation properties, the DEETGE-CAL-Tat peptide represents a novel, and potentially promising new therapeutic modality for the treatment of GCI.",
keywords = "Cardiac arrest, Cognitive defect, Hippocampus CA1 region, Neuroprotection, Peptide, Reactive oxidative species",
author = "Jingyi Tu and Xi Zhang and Ying Zhu and Yongxin Dai and Ning Li and Fang Yang and Quanguang Zhang and Brann, {Darrell W} and Ruimin Wang",
year = "2015",
month = "11",
day = "4",
doi = "10.1523/JNEUROSCI.1304-15.2015",
language = "English (US)",
volume = "35",
pages = "14727--14739",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "44",

}

TY - JOUR

T1 - Cell-permeable peptide targeting the Nrf2-keap1 interaction

T2 - A potential novel therapy for global cerebral ischemia

AU - Tu, Jingyi

AU - Zhang, Xi

AU - Zhu, Ying

AU - Dai, Yongxin

AU - Li, Ning

AU - Yang, Fang

AU - Zhang, Quanguang

AU - Brann, Darrell W

AU - Wang, Ruimin

PY - 2015/11/4

Y1 - 2015/11/4

N2 - The current study examined efficacy of a small Tat (trans-activator of transcription)-conjugated peptide activator of the Nrf2 (nuclear factor-E2-related factor-2) antioxidant/cell-defense pathway as a potential injury-specific, novel neuroprotectant against global cerebral ischemia (GCI).A competitive peptide, DEETGE-CAL-Tat, was designed to facilitate Nrf2 activation by disrupting interaction of Nrf2 with Keap1 (kelch-like ECH-associated protein 1), a protein that sequesters Nrf2 in the cytoplasm and thereby inactivates it. The DEETGECAL-Tat peptide contained the critical sequence DEETGE for the Nrf2-Keap1 interaction, the cell transduction domain of the HIV-Tat protein, and the cleavage sequence of calpain, which is sensitive to Ca2+ increase and allows injury-specific activation of Nrf2. Using an animal model of GCI, we demonstrated that pretreatment with the DEETGE-CAL-Tat peptide markedly decreased Nrf2 interaction with Keap1 in the rat hippocampal CA1 region after GCI, and enhanced Nrf2 nuclear translocation and DNA binding. The DEETGE-CAL-Tat peptide also induced Nrf2 antioxidant/cytoprotective target genes, reduced oxidative stress, and induced strong neuroprotection and marked preservation of hippocampal-dependent cognitive function after GCI. These effects were specific as control peptides lacked neuroprotective ability. Intriguingly, the DEETGE-CAL-Tat peptide effects were also injury specific, as it had no effect upon neuronal survival or cognitive performance in sham non ischemic animals. Of significant interest, peripheral, post ischemia administration of the DEETGE-CAL-Tat peptide from days 1-9 after GCI also induced robust neuroprotection and strongly preserved hippo campal-dependent cognitive function. Based on its robust neuro protective and cognitive-preserving effects, and its unique injury-specific activation properties, the DEETGE-CAL-Tat peptide represents a novel, and potentially promising new therapeutic modality for the treatment of GCI.

AB - The current study examined efficacy of a small Tat (trans-activator of transcription)-conjugated peptide activator of the Nrf2 (nuclear factor-E2-related factor-2) antioxidant/cell-defense pathway as a potential injury-specific, novel neuroprotectant against global cerebral ischemia (GCI).A competitive peptide, DEETGE-CAL-Tat, was designed to facilitate Nrf2 activation by disrupting interaction of Nrf2 with Keap1 (kelch-like ECH-associated protein 1), a protein that sequesters Nrf2 in the cytoplasm and thereby inactivates it. The DEETGECAL-Tat peptide contained the critical sequence DEETGE for the Nrf2-Keap1 interaction, the cell transduction domain of the HIV-Tat protein, and the cleavage sequence of calpain, which is sensitive to Ca2+ increase and allows injury-specific activation of Nrf2. Using an animal model of GCI, we demonstrated that pretreatment with the DEETGE-CAL-Tat peptide markedly decreased Nrf2 interaction with Keap1 in the rat hippocampal CA1 region after GCI, and enhanced Nrf2 nuclear translocation and DNA binding. The DEETGE-CAL-Tat peptide also induced Nrf2 antioxidant/cytoprotective target genes, reduced oxidative stress, and induced strong neuroprotection and marked preservation of hippocampal-dependent cognitive function after GCI. These effects were specific as control peptides lacked neuroprotective ability. Intriguingly, the DEETGE-CAL-Tat peptide effects were also injury specific, as it had no effect upon neuronal survival or cognitive performance in sham non ischemic animals. Of significant interest, peripheral, post ischemia administration of the DEETGE-CAL-Tat peptide from days 1-9 after GCI also induced robust neuroprotection and strongly preserved hippo campal-dependent cognitive function. Based on its robust neuro protective and cognitive-preserving effects, and its unique injury-specific activation properties, the DEETGE-CAL-Tat peptide represents a novel, and potentially promising new therapeutic modality for the treatment of GCI.

KW - Cardiac arrest

KW - Cognitive defect

KW - Hippocampus CA1 region

KW - Neuroprotection

KW - Peptide

KW - Reactive oxidative species

UR - http://www.scopus.com/inward/record.url?scp=84946430622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946430622&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.1304-15.2015

DO - 10.1523/JNEUROSCI.1304-15.2015

M3 - Article

C2 - 26538645

AN - SCOPUS:84946430622

VL - 35

SP - 14727

EP - 14739

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 44

ER -